AVITA Medical Inc

RCEL remains in a sustained Stage 4 decline with persistent lower highs and lower lows and price below all key moving averages. Oversold conditions at current levels increase the risk of a bounce, so under the speculative strategy we defer selling to rallies into resistance around the EMAs to ensure asymmetric entry.

• ↑Q1 2026 revenue of $19.3M (+4% YoY, +10% sequential) signals top‐line recovery
• ↑Operating expenses down 11% YoY to $24.5M, boosting cost discipline
• ↓Q1 net loss of $10.6M indicates ongoing unprofitability